SMS-oncology appoints Dr. Stephan Winckels as CMO
SMS-oncology, a full service CRO solely dedicated to oncology, today announces the expansion of its management team by appointing Stephan Winckels MD PhD as Chief Medical Officer (CMO).
Dr. Winckels carries over ten years of experience in cancer research and pharmaceutical industry in both big pharma as well as CROs. Trained as an MD, Dr. Winckels obtained his PhD in Medical Physiology. From 2008 onward, Stephan decided to dedicate his career to oncology and started as a resident in pathology at University Medical Center Utrecht. In 2009, Stephan joined the pharmaceutical industry following Wyeth (now Pfizer), Boehringer Ingelheim and the CRO Julius Clinical in which he fulfilled roles as a medical monitor, project manager, protocol author, safety physician, proposal writer and medical lead, focusing on phase I-III oncology studies. Throughout his career, he gained strong experience in clinical oncology drug development and operational insights.
Dr. Winckels joined SMS-oncology three years ago to head the department of Medical Affairs. Today’s promotion is the evaluation of Dr. Winckels demonstrated results, experience and leadership, which benefited the company’s strong performance.
Ms Philine van den Tol, Chief Executive Officer (CEO) at SMS-oncology: “We are pleased to have Stephan join our executive team. His strategic planning and decision-making capabilities combined with extensive industry knowledge is an excellent addition to the company’s growth and development plan. The management team is now further completed and I am confident to say that we possess the right mix of competencies to achieve SMS-oncology’s aim to become the leading oncology CRO in the world.”
Dr. Winckels is delighted to strengthen the management team in his new position as CMO and further contribute to the advancement of medical oncology: “In the upcoming years big data may be the turning point for the clinical trial industry. To ensure effective implementation and to bypass any loss or valuable information we are turning our focus to smart, adaptive and flexible study designs. By integrating our expertise with the newest advances in oncology, we can ensure our current and future clients a successful transition from an oncological compound to meaningful trial results.”
The management team now consists of: Ms. Philine van den Tol (CEO), Mr. Raymond Hoffmans PhD (CBDO), Ms. Eveline Verheijen (COO), Mr. Stephan Winckels MD, PhD (CMO), and Mr. René de Keijzer (CFO).